Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179

Ginkgo Bioworks Holdings, Inc.

Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.
Zymergen stockholders received 0.9179 Ginkgo Class A shares per Zymergen share held.
Zymergen shares will cease trading on Nasdaq; Ginkgo common stock continues on NYSE as DNA.
Expected to enhance Ginkgo's platform with added automation, software, and biological engineering expertise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.